Mark W. Ledeboer

1.3k total citations
18 papers, 607 citations indexed

About

Mark W. Ledeboer is a scholar working on Molecular Biology, Organic Chemistry and Genetics. According to data from OpenAlex, Mark W. Ledeboer has authored 18 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Organic Chemistry and 3 papers in Genetics. Recurrent topics in Mark W. Ledeboer's work include Carbohydrate Chemistry and Synthesis (4 papers), Influenza Virus Research Studies (2 papers) and Respiratory viral infections research (2 papers). Mark W. Ledeboer is often cited by papers focused on Carbohydrate Chemistry and Synthesis (4 papers), Influenza Virus Research Studies (2 papers) and Respiratory viral infections research (2 papers). Mark W. Ledeboer collaborates with scholars based in United States and Germany. Mark W. Ledeboer's co-authors include Kathlyn A. Parker, Dale L. Boger, Qing Jin, Marc Jacobs, G. Malojcic, Michael P. Clark, Emanuele Perola, Paul S. Charifson, Joshua R. Leeman and Azin Nezami and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and PLoS ONE.

In The Last Decade

Mark W. Ledeboer

18 papers receiving 599 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Ledeboer United States 12 253 247 155 68 67 18 607
Souvik Banerjee United States 16 281 1.1× 432 1.7× 43 0.3× 53 0.8× 19 0.3× 31 777
Robert G. Gentles United States 17 221 0.9× 345 1.4× 146 0.9× 27 0.4× 17 0.3× 36 669
Arindam Talukdar India 16 284 1.1× 406 1.6× 43 0.3× 51 0.8× 8 0.1× 46 839
Sangmi Oh South Korea 17 397 1.6× 429 1.7× 97 0.6× 114 1.7× 5 0.1× 42 868
Jason D. Burch Canada 14 426 1.7× 134 0.5× 27 0.2× 146 2.1× 7 0.1× 25 721
Maude Giroud Germany 15 232 0.9× 376 1.5× 138 0.9× 34 0.5× 3 0.0× 27 774
Paul E. Wiedeman United States 13 184 0.7× 179 0.7× 20 0.1× 27 0.4× 30 0.4× 20 437
Denis R. St. Laurent United States 17 311 1.2× 216 0.9× 166 1.1× 72 1.1× 2 0.0× 27 768
John A. Wos United States 13 285 1.1× 249 1.0× 39 0.3× 33 0.5× 6 0.1× 34 565
Scott Martin United Kingdom 15 254 1.0× 407 1.6× 142 0.9× 38 0.6× 7 0.1× 32 955

Countries citing papers authored by Mark W. Ledeboer

Since Specialization
Citations

This map shows the geographic impact of Mark W. Ledeboer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Ledeboer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Ledeboer more than expected).

Fields of papers citing papers by Mark W. Ledeboer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Ledeboer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Ledeboer. The network helps show where Mark W. Ledeboer may publish in the future.

Co-authorship network of co-authors of Mark W. Ledeboer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Ledeboer. A scholar is included among the top collaborators of Mark W. Ledeboer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Ledeboer. Mark W. Ledeboer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fast, Eva M., Thomas W. Soare, Michael DeRan, et al.. (2022). Transplanted organoids empower human preclinical assessment of drug candidate for the clinic. Science Advances. 8(27). eabj5633–eabj5633. 17 indexed citations
2.
Daniels, Matthew H., G. Malojcic, Susan L. Clugston, et al.. (2022). Discovery and Optimization of Highly Selective Inhibitors of CDK5. Journal of Medicinal Chemistry. 65(4). 3575–3596. 18 indexed citations
3.
Quentin, Dennis, Oleg Sitsel, Felipe Merino, et al.. (2020). Structural basis of TRPC4 regulation by calmodulin and pharmacological agents. eLife. 9. 49 indexed citations
4.
Ledeboer, Mark W., Matthew H. Daniels, G. Malojcic, et al.. (2019). Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. ACS Medicinal Chemistry Letters. 10(11). 1579–1585. 44 indexed citations
5.
Mündel, Peter, Mark W. Ledeboer, Matthew H. Daniels, et al.. (2019). SUN-190 GFB-887, a small molecule inhibitor of TRPC5, protects against podocyte injury and attenuates proteinuria in models of FSGS. Kidney International Reports. 4(7). S237–S237. 4 indexed citations
6.
Boyd, Michael J., Upul K. Bandarage, Wenxin Gu, et al.. (2015). Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(9). 1990–1994. 26 indexed citations
7.
Byrn, Randal A., Steven J.M. Jones, Michael P. Clark, et al.. (2014). Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit. Antimicrobial Agents and Chemotherapy. 59(3). 1569–1582. 149 indexed citations
8.
Salituro, Francesco G., et al.. (2013). Dual p38/JNK Mitogen Activated Protein Kinase Inhibitors Prevent Ozone-Induced Airway Hyperreactivity in Guinea Pigs. PLoS ONE. 8(9). e75351–e75351. 7 indexed citations
9.
Wang, Tiansheng, Mark W. Ledeboer, John P. Duffy, et al.. (2010). ChemInform Abstract: A Novel Chemotype of Kinase Inhibitors: Discovery of 3,4‐Ring Fused 7‐Azaindoles and Deazapurines as Potent JAK2 Inhibitors.. ChemInform. 41(21). 1 indexed citations
10.
Wang, Tiansheng, Mark W. Ledeboer, John P. Duffy, et al.. (2009). A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(1). 153–156. 40 indexed citations
11.
Cao, Jingrong, Huai Gao, Guy W. Bemis, et al.. (2009). Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(10). 2891–2895. 36 indexed citations
12.
Boger, Dale L., et al.. (2000). ChemInform Abstract: Total Synthesis and Comparative Evaluation of Luzopeptin A—C and Quinoxapeptin A—C.. ChemInform. 31(10). 1 indexed citations
13.
Boger, Dale L., et al.. (1999). Totalsynthese von Chinoxapeptin A–C: Bestimmung der absoluten Konfiguration. Angewandte Chemie. 111(16). 2533–2536. 7 indexed citations
14.
Boger, Dale L., et al.. (1999). Total Synthesis of Luzopeptins A−C. Journal of the American Chemical Society. 121(5). 1098–1099. 37 indexed citations
15.
Boger, Dale L., et al.. (1999). Total Synthesis and Comparative Evaluation of Luzopeptin A−C and Quinoxapeptin A−C. Journal of the American Chemical Society. 121(49). 11375–11383. 39 indexed citations
16.
Boger, Dale L., et al.. (1999). Total Synthesis of Quinoxapeptin A-C: Establishment of Absolute Stereochemistry. Angewandte Chemie International Edition. 38(16). 2424–2426. 31 indexed citations
17.
Parker, Kathlyn A. & Mark W. Ledeboer. (1996). Asymmetric Reduction. A Convenient Method for the Reduction of Alkynyl Ketones. The Journal of Organic Chemistry. 61(9). 3214–3217. 96 indexed citations
18.
Nutaitis, Charles F. & Mark W. Ledeboer. (1992). PREPARATION OF BENZO[c-2,7]NAPHTHYRIDINE. Organic Preparations and Procedures International. 24(2). 143–146. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Souvik Banerjee Breakdown of academic impact, for papers by Robert G. Gentles Breakdown of academic impact, for papers by Arindam Talukdar Breakdown of academic impact, for papers by Sangmi Oh Breakdown of academic impact, for papers by Jason D. Burch Breakdown of academic impact, for papers by Maude Giroud Breakdown of academic impact, for papers by Paul E. Wiedeman Breakdown of academic impact, for papers by Denis R. St. Laurent Breakdown of academic impact, for papers by John A. Wos Breakdown of academic impact, for papers by Scott Martin
Rankless by CCL
2026